News headlines about Teligent (NASDAQ:TLGT) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Teligent earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6014468166597 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

TLGT has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Teligent from a “strong sell” rating to a “hold” rating in a research note on Friday, October 13th. TheStreet cut shares of Teligent from a “c-” rating to a “d+” rating in a research note on Wednesday, November 1st. Finally, Canaccord Genuity cut shares of Teligent from a “buy” rating to a “hold” rating and lowered their target price for the stock from $9.00 to $5.00 in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Shares of Teligent (NASDAQ TLGT) traded down $0.01 during midday trading on Wednesday, hitting $3.01. 103,498 shares of the stock traded hands, compared to its average volume of 519,408. Teligent has a one year low of $2.75 and a one year high of $9.54. The stock has a market cap of $152.19, a PE ratio of -13.09, a PEG ratio of 57.00 and a beta of 1.07. The company has a debt-to-equity ratio of 2.23, a current ratio of 3.28 and a quick ratio of 2.71.

Teligent (NASDAQ:TLGT) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.07). Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The company had revenue of $13.65 million for the quarter, compared to analysts’ expectations of $19.12 million. During the same period in the prior year, the firm earned $0.01 earnings per share. The firm’s quarterly revenue was down 15.5% on a year-over-year basis. sell-side analysts forecast that Teligent will post -0.2 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Teligent (TLGT) Share Price” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Insider Buying and Selling by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with's FREE daily email newsletter.